ThromboGenics finishes patient enrollment in 2 drug trials

11/6/2009 | Reuters

Belgian biotech firm ThromboGenics finished enrolling patients in a U.S. Phase III trial of microplasmin, its candidate for back-of-the-eye disease. The company also concluded patient recruitment for a Phase II trial of TB-402, an experimental anti-clotting drug co-developed with Swedish firm BioInvent.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC